For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and Tafamidis meglumine represents a genuine advancement . These novel therapies preserve the transthyretin protein, slowing its destructive build-up and lessening the impact of the condition . Patients are now experiencin